, cPLA 2 mRNA levels and enzyme activity were significantly reduced (3.6-and 3-fold, respectively). Reduced levels of cPLA 2 were also observed in preneoplastic aberrant crypt foci (ACF), a distinct morphological alteration that represents an early stage in the pathogenesis of colon tumors. Furthermore, the reciprocal expression patterns of these two genes were found to occur in human colorectal cancers (CRC). Examination of the activity of the secretory phospholipases A 2 (sPLA 2 ) and expression of the groups V and X sPLA 2 s revealed no compensatory increase in tumor tissue. As cPLA 2 has been shown to be involved in TNF-α-induced apoptosis in certain cell types, and TNF-α expression is significantly enhanced in AOM-induced tumors (2.8-fold), we examined the role of cPLA 2 in TNF-α-induced apoptosis of cultured mouse colonocytes (YAMC). The specific cPLA 2 inhibitor, AAC-OCF 3 (arachidonoyl trifluoromethyl ketone), was able to protect colonocytes from TNF-α-induced apoptosis in vitro. In summary, our data demonstrate an inverse relationship between COX-2 and cPLA 2 expression in both AOMinduced mouse colon tumors and human CRC and suggest that down regulation of cPLA 2 may attenuate TNF-α mediated apoptosis during tumorigenesis and facilitate tumor progression.
Introduction
An important pathway in the pathogenesis of colorectal cancer is the generation of prostaglandins (PGs) via the cyclooxygenase-2 (COX-2) (1). COX-2, an inducible form of cyclooxygenase, plays a major role in the synthesis of PGs from arachidonic acid (AA) and is rapidly induced by growth factors, inflammatory cytokines and oncogenes (2) (3) (4) . AA is provided by the phospholipase A 2 s through hydrolysis of membrane phospholipids at the sn-2 position. Apart from being a precursor of PGs, intracellular AA can also act as a death mediator via activation of sphingomyelinase, which hydrolyzes sphingomyelin to ceramide, an inducer of apoptosis (5, 6) . It has been demonstrated in cell lines that this pathway plays a critical role in promoting apoptosis induced by tumor necrosis factor α (TNF-α) (7) (8) (9) .
To date, at least 10 mammalian PLA 2 s have been classified on the basis of their distinct biochemical features. Three important groups include the cytosolic PLA 2 (cPLA 2 ), the secretory PLA 2 s (sPLA 2 ) and a Ca 2ϩ -independent PLA 2 (iPLA 2 ) (10). cPLA 2 (85 kDa) is the major intracellular form of PLA 2 . It is widely expressed and plays an essential role in stimulus-induced AA release (11, 12) . Because of its important role in generating PGs, a role for cPLA 2 in intestinal tumorigenesis has also been suggested. Two recent studies demonstrated that cPLA 2 expression is elevated in small intestinal polyps in both Apc Min and Apc n716 mice (13, 14) . Furthermore, deletion of the cPLA 2 gene significantly suppressed Apc Min or Apc n716 -induced tumorigenesis in the small intestine. In both studies, however, elevated cPLA 2 was not observed in colon tumors, nor did deletion of the cPLA 2 gene reduce tumorigenesis in this organ. On the contrary, cPLA 2 deletion was accompanied by increased numbers or size of colon polyps, arguing that the physiological function of cPLA 2 and its role in tumorigenesis may differ within specific regions of the gut.
Secretory phospholipase A 2 s comprise a family of PLA 2 enzymes sharing several biochemical characteristics, including a low molecular mass (14 kDa) , the presence of six to eight disulfide bonds, and an absolute catalytic requirement for millimolar concentrations of Ca 2ϩ (10) . Among the seven sPLA 2 identified in mammals, groups IIA, V and X are expressed in mouse colon (13) (14) (15) . sPLA 2 group IIA, the inflammatory sPLA 2 , has been proposed to play a role in intestinal tumorigenesis; transgenic mice overexpressing group IIA are resistant to Apc Min -induced intestinal tumorigenesis (16) . The group V sPLA 2 shares the greatest homology with group IIA and functions in a similar manner (10) . Studies with immune cells isolated from sPla2g2a -/-mice demonstrate that group V sPLA 2 can substitute group IIA for AA production (17, 18) . Group X sPLA 2 , a new member of the sPLA 2 family, is found to be highly expressed in the large intestine. Like cPLA 2 , group X sPLA 2 mRNA levels are increased in small intestinal polyps in Apc n716 mice, suggesting a concerted role for phospholipases in AA release and subsequent COX-2-mediated PG synthesis, thus contributing to intestinal tumorigenesis (14) .
To further characterize the role of the cytosolic and secretory phospholipases in colon tumorigenesis, we examined the expression and functional status of these enzymes in colon tumors induced by the organotropic colon carcinogen, azoxy- Quantitative analysis of RPA data was performed using NIH image analysis software. Statistical analysis was performed using the Generalized linear model procedure followed by PDIFF post-hoc analysis for comparing the means. Each column represents the mean Ϯ SE. *P Ͻ 0.05. (C) Comparison of COX-2 protein levels in normal colon and tumor tissues. Equivalent amounts of total protein extract from normal colon and tumor tissues were separated by SDS-PAGE and immunoblotted with antibody against COX-2 or β-actin. methane (AOM). Our laboratory has shown that sensitive strains of mice treated with AOM develop up to 40 tumors, restricted primarily to the distal colon (19) . The AOM model has thus provided considerable insight into our understanding of signaling pathways that may be dysregulated during colon tumorigenesis (20) (21) (22) (23) (24) . In the present study, a striking reduction in cPLA 2 expression was found in carcinogeninduced pre-neoplastic lesions and tumors. In addition, cPLA 2 reduction occurred despite enhanced COX-2 expression and PGE 2 overproduction, whereas expression of the major secretory phospholipases, group V and group X, were unaltered. The data suggest a dissociation between cPLA 2 activity and PG production during colon tumorigenesis. In addition, the reciprocal expression patterns of cPLA 2 and COX-2 were also found to occur in human colorectal cancers (CRC). Furthermore, in vitro evidence is obtained that a reduction in cPLA 2 levels may compromise the ability of TNF-α to induce apoptosis in colonocytes, raising the possibility that cPLA 2 plays an important role in regulating tumor promotion in the colon.
Materials and methods

Animals and test materials
A/J mice were purchased from the Jackson Laboratories (Bar Harbor, ME). AOM, cyclohexamide and proteinase inhibitor cocktail were obtained from Sigma (St Louis, MO). The cPLA 2 inhibitor arachidonoyl trifluoromethyl ketone (AACOCF 3 ) was purchased from BIOMOL Research Laboratories (Plymouth Meeting, PA). Recombinant mouse TNF-α was purchased from Chemicon (Temecula, CA). The RiboQuant multiprobe RNase protection assay system, including the TNF-α template, was obtained from Pharmingen (San Diego, CA). Rabbit anti-mouse cPLA 2 was generously provided by Dr A.V.Cybulsky (McGill University, Canada). Monoclonal mouse-anti human cPLA 2 antibody was purchased from Upstate (Lake Placid, NY). Mouse anti-β-actin antibody was purchased from Sigma. Rabbit anti-COX 2 antibody, and the assay kits for PGE 2 and cPLA 2 were purchased from Cayman Chemical (Ann Arbor, MI). The sPLA 2 assay kit was purchased from Assay Design (Ann Arbor, MI). Young adult mouse colonocytes were generously provided by Dr R.H.Whitehead (Ludwig Institute for Cancer Research, Switzerland).
Animal treatment and tissue sample preparation
Five-week-old male A/J mice were housed in a temperature-controlled environment (23°C Ϯ 1) with a 12 h light/dark cycle. Mice were provided with Purina laboratory rodent chow 5001 and water ad libitum. After an acclimation period of 1 week, mice were divided randomly into two groups. One group was treated with AOM dissolved in saline by i.p. injection at a dose of 10 mg/kg body wt once per week for 6 weeks. The other group received saline and served as vehicle controls. Mice were killed 24 weeks 308 after the last dose. The entire colon was removed and flushed with ice-cold PBS buffer. Colons were slit open longitudinally. Colon tumors from the AOM treatment group and normal distal colons from the control group were dissected and tissues were divided into macroscopically similar portions. The portions for RNA and protein were immediately frozen in liquid nitrogen and stored at -80°C. The remaining portion for paraffin embedding was fixed in 10% neutral-buffered formalin for 6 h and embedded in paraffin for subsequent histopathological examination and immunostaining.
RNase protection assay
Total cellular RNA was isolated from frozen normal colons and tumor tissues using the Qiagen RNeasy kit (Qiagen, Valencia, CA) following the manufacturer's instructions. mRNA levels for the genes examined were quantified using the RiboQuant multiprobe RNase protection assay (RPA) system. A customized template set containing TNF-α and GAPDH was used to probe the RNA samples. GAPDH was used as an internal control. To make probes for the other genes, an RT-PCR reaction was carried out according to a standard protocol. The primers used in the PCR reaction were as follows: cPLA 2 , 5Ј-GGA TGA GCA TGA CCC TGA GT-3Ј and 5Ј-GGC AAA CAT CAG CTC TGA CA-3Ј; COX 2 , 5Ј-TCC TCA CAT CCC TGA GAA CC-3Ј and 5Ј-CTC ATC ACC CCA CTC AGG AT-3Ј; sPLA 2 gX, 5Ј-GAC CTG GAC CCG GAT TCA GC-3Ј and 5Ј-CTT GGG AGA GTC CTT CTC AC-3Ј; sPLA 2 gV, 5Ј-CGG GGG GCT TGC TAG AAC TCA A-3Ј and 5Ј-AAG AGG GTT GTA AGT CCA GAG G-3Ј; sPLA 2 M-type receptor, 5Ј-TCG CCT ACA CGT CCA GTG GT-3Ј and 5Ј-CTG CCA GCC AGC CTT CTC AT-3Ј; and HPRT (loading control), 5Ј-GTA ATG ATC AGT CAA CGG GGG AC-3Ј and 5Ј-CCA GCA AGC TTG CAA CCT TAA CCA-3Ј. cDNA fragments of different length were cloned into the pGEM-T Easy vector (Promega, Madison, WI). The 32 P-labeled anti-sense RNA probes were synthesized using the RiboQuant In Vitro Transcription kit according to the manufacturer's instructions. RNA samples (5 µg) were incubated with the anti-sense probes overnight at 56°C and then digested by treatment with RNase. The protected double-stranded RNA fragments were resolved on 7% denaturing gels, which were then exposed to X-ray film at -70°C. Image densitometry was performed using NIH image software.
Western blot analysis
Normal colons and tumor tissue were homogenized in RIPA buffer containing protease inhibitor cocktail and incubated on ice for 30 min. Samples were then centrifuged at 10 000 g for 15 min and the total protein content of the supernatant was quantified with the Bio-Rad DC Protein Assay (Bio-Rad Laboratories, Hercules, CA). Protein (30 µg) was separated on a 10% SDS-PAGE gel and then electrotransferred onto a nitrocellulose membrane. The membrane was probed with the following primary antibodies: anti-cPLA 2 (1:1000), anti-COX 2 antibody (1:1000) or anti-β-actin antibody (1:1000). For cPLA 2 and β-actin, the blot was incubated with anti-rabbit and anti-mouse horseradish peroxidase-conjugated secondary antibody, respectively, and visualized using the ECL Western blot analysis system (Santa Cruz Biotechnology, CA). For COX-2, the alkaline phosphatase-conjugated secondary antibody and ECL system provided by the WesternBreeze kit (Invitrogen, Carlsbad, CA) was used according to the manufacturer's instructions.
PGE 2 levels determination
Normal control colons and AOM-treated tumor tissues were homogenized in ice-cold PBS buffer containing 1 mM EDTA and 10 µM indomethacin (Sigma), mixed with an equal volume of ethanol and then centrifuged at 1500 g for 10 min. The supernatant was acidified to a pH of 4 by addition of acetate buffer, and then applied to a methanol-activated C 18 reverse phase column (Waters Corporation, Milford, MA), which was then rinsed with water and hexane. The organic phase was collected by elution with ethyl acetate containing 1% methanol, which was later evaporated under a nitrogen stream. The final purified organic phase was analyzed for PGE 2 levels using the Prostaglandin E 2 E1A-Monoclonal kit, based on the competition between PGE 2 and a PGE 2 -acetylcholinesterase conjugate for a limited amount of PGE 2 monoclonal antibody. cPLA 2 activity determination Equal amounts of normal untreated control colons and tumor samples were homogenized in 500 µl ice-cold PBS buffer containing 1 mM EDTA and centrifuged at 10 000 g for 15 min at 4°C. The supernatant was treated with 5 µM bromoenol lactone for 15 min at 25°C to inhibit the activity of iPLA 2 and then filtered through a cellulose membrane filter with a molecular weight cut-off of 30 000 (Millipore) to remove any residual sPLA 2 . The purified sample was then incubated with the substrate, arachidonoyl Thio-PC. Hydrolysis of the substrate at the sn-2 position by PLA 2 releases free thiol, which was then detected colorimetrically using Ellman's reagent on a microplate reader (405 nm). sPLA 2 activity determination Equal amounts of normal control colon tissues and tumor samples from AOMtreated mice were homogenized in 500 µl ice-cold PBS buffer and centrifuged at 10 000 g for 15 min at 4°C. Samples of 50 µl of the supernatant were incubated with HEPC (2-hexadecanoylthio-1-ethylphosphorylcholine), a specific substrate for the sPLA 2 s, but not metabolized by cPLA 2 (25) . HEPC is converted into a thiol molecule, which is detected colorimetrically using Ellman's reagent (405 nm).
Altered arachidonic acid metabolism in colon tumors
Immunohistochemistry 5-µM formalin-fixed, paraffin-embedded mouse and human colon tissue sections were incubated with primary antibody (anti-COX-2 1:200, anti-mouse cPLA 2 1:300, anti-human cPLA 2 1:100) overnight at 4°C. Sections were washed with PBS and incubated with corresponding biotinylated secondary antibody (1:100) (Vector Laboratories, Burlingame, CA) at room temperature for 30 min. After washing, the sections were incubated with avidin-biotin peroxidase complex provided by Vectastain Elite ABC kit (Vector Laboratories) at room temperature for 30 min. Color was developed with 3,3-diaminobenzi-309 dine as the substrate. Sections were then counterstained with hematoxylin. As a negative control, the duplicate sections were immunostained in parallel with 10% goat serum in place of the primary antibody. Analysis of cPLA 2 and COX-2 in human colon tumors Human colorectal cancer tumors and paired normal adjacent mucosal tissues were collected from surgically resected specimens of primary CRC patients following approval by the Institutional Ethics Committee. Tissue samples were immediately frozen in liquid nitrogen and stored at -80°C for subsequent RNA isolation and semi-quantitative RT-PCR analysis. The primers used in the PCR reaction were as follows: cPLA 2 , 5Ј-CTC ATG CCC AGA CCT ACG ATT-3Ј and 5Ј-TAA TAC GAC TCA CTA TAG GGC GTC AGG TTT GAC-3Ј; COX-2, 5Ј-GAT TCA AAT GAG ATT GTG GAA AAA TTG CTT-3Ј and 5Ј-GAT AGC CAC TCA AGT GTT GCA CA-3Ј; GAPDH, 5Ј-CCA TGG AGA AGG CTG GG-3Ј and 5Ј-GGT CAT CCA TGA CAA CTT TG-3Ј.
Cell culture and treatments
Experiments were carried out using the conditionally immortalized murine colonic epithelial cells (YAMC) (26) . YAMC cells express the IFN-γ-induced by guest on November 24, 2016 http://carcin.oxfordjournals.org/ Downloaded from heat-labile SV40 large T antigen, which is active only at 33°C. All cells were grown to 95% confluence at 33°C with 5% CO 2 on 24-well plate in RPMI 1640 media supplemented with 5% FBS, ITS (insulin 6.25 ng/ml, transferrin 6.25 µg/ml, selenious acid 6.25 ng/ml, linoleic acid 5.35 mg/ml and bovine serum albumin 1.25 mg/ml), 5 IU/ml of murine IFN-γ, 100 IU/ml penicillin and 100 µg/ml streptomycin. Cells were pre-incubated with different concentrations of AACOCF 3 or BPB for 2 h, and then sensitized to TNF-α-induced cell death by incubating with 25 µg/ml cycloheximide for 1 h. TNF-α (25 ng/ml) was added to each well and cells were then further incubated for 6 h. For quantification of apoptotic cells, both attached and collected floating cells were briefly trypsinized into a single-cell suspension. Cells were then collected by centrifugation at 1000 r.p.m. for 10 min, fixed in Carnoy's Fig. 3 . Comparison of PGE 2 levels in normal mouse colon and tumor tissue. Tissue samples (normal, n ϭ 3; tumor, n ϭ 5) were homogenized in PBS buffer containing 1 mM EDTA and 10 µM indomethacin. Lipids were extracted using a C 18 reverse phase column and PGE 2 levels were determined by ELISA using PGE 2 monoclonal antibody (*P Ͻ 0.01). . Tissue homogenates were treated with 5 µM bromoenol lactone to inhibit the activity of iPLA 2 and filtered through a cellulose membrane with a molecular weight cut-off of 30 000 to remove residual sPLA 2 . cPLA 2 activity was then measured using arachidonoyl Thio-PC as a substrate (*P Ͻ 0.05). 310 solution (1:3 v/v glacial acetic acid:methanol, prepared fresh), dropped on a glass slide and stained with Hoechst 33258 (Sigma) for 10 min at room temperature. Cells with condensed nuclei were counted as apoptotic cells. For determination of cPLA 2 activity, YAMC cells cultured in a 35 mm dish were incubated with TNF-α following pre-treatment with AACOCF 3 and CHX. One hour after the incubation, cells were washed twice with ice-cold PBS and homogenized in PBS containing 1 mM EDTA. cPLA 2 activity was immediately assayed as described above.
Statistical analysis
The Generalized linear model procedure using SAS software was applied. Significant differences were determined by the probability of difference (PDIFF) between the means. A P-value Ͻ0.05 was considered statistically significant.
Results
COX-2 and PGE 2 levels in AOM-induced colon tumors
COX-2 levels are typically elevated in rodent colon tumor models (4, 27) . As an initial step to determine COX-2 status in AOM-induced A/J colon adenocarcinomas, we quantified COX-2 mRNA expression by quantitative RPA. As shown in Figure 1A and B, COX-2 mRNA levels were below the level of detection in vehicle-treated control colon tissue, but significantly increased (3.7-fold, P Ͻ 0.01) in the tumors. Consistent with elevated mRNA levels, western blot analysis ( Figure 1C ) also indicated a marked increase in COX-2 protein in adenocarcinomas compared with vehicletreated controls. This was also confirmed by enhanced COX-2 immunostaining in tumors compared with adjacent normal- (Figure 2A and C). Furthermore, markedly enhanced COX-2 immunostaining in the large dyplastic ACF ( Figure 2B ) demonstrates that COX-2 overexpression is an early event during colon tumorigenesis. To determine if overexpression of COX-2 was associated with overproduction of PGE 2 , a major eicosanoid product believed to be involved in COX-2-mediated colon tumorigenesis (28, 29) , PGE 2 levels were measured by ELISA and found to be significantly elevated (3.4-fold, P Ͻ 0.01) within excised adenocarcinomatous tissue (Figure 3) . The overproduction of PGE 2 mediated by COX-2 may therefore participate in AOM-induced mouse colon tumorigenesis. Expression and functional status of cPLA 2 in AOM-induced colon tumors cPLA 2 plays a key role in the generation of AA from internal cell membranes. To investigate the possibility that COX-2-induced PGE 2 overproduction is coordinately regulated with cPLA 2 activity, we examined the expression of cPLA 2 using both RPA and western blot analysis. Despite high levels of PGE 2 , a significant reduction (3.6-fold, P Ͻ 0.01) in cPLA 2 mRNA levels was observed in AOM-induced colon tumors compared to vehicle-treated controls ( Figure 4A and B). This reduction in transcript was associated with a decrease in protein levels as shown by western blot analysis ( Figure 4C ). To determine whether the observed reduction in cPLA 2 mRNA and protein was accompanied by altered enzymatic activity, we examined the functional status of cPLA 2 in both tumors and vehicle-treated control colons. As shown in Figure 4D , a significant decrease in cPLA 2 activity was observed in adenocarcinomas (3.5-fold, P Ͻ 0.01). Taken together, these results indicate that cPLA 2 expression is not correlated with high levels of COX-2 and PGE 2 overproduction in AOMinduced colon tumors. cPLA 2 immunostaining further demonstrates a relative reduction in protein levels in the preneoplastic lesions, including hyperplastic ( Figure 5B ) and dysplastic ACF ( Figure 5C ), relative to normal colonic crypts ( Figure 5A ). This finding indicates that reduction of cPLA 2 , like COX-2 overexpression, occurs early during colon tumorigenesis.
Status of sPLA 2 s in AOM-induced colon tumors
A reduction of cPLA 2 in the tumors suggests alternative mechanisms for the supply of AA to COX-2 for PG production, possibly mediated by the sPLA 2 s. As A/J mice carry a nonsense mutation in the major colon sPLA 2 gene, group IIA sPLA 2 (30) , it was of interest to determine whether additional secretory phospholipase(s) may be compensatory induced in colon tumors. As an initial step to evaluate this possibility, we examined total sPLA 2 activity in AOM-induced tumors and by guest on November 24, 2016 http://carcin.oxfordjournals.org/ Downloaded from Fig. 6 . Examination of total sPLA 2 activity and expression of group X and group V sPLA 2 and the M-type sPLA 2 receptor. (A) Total sPLA 2 activity in normal colon and tumor tissues was determined using HEPC, a general sPLA 2 substrate that is not reactive to cPLA 2 . (B) Group X and group V sPLA 2 and M-type sPLA 2 receptor (M-R) mRNA levels in normal colon and tumor tissue were determined by RPA. HPRT was used as a loading control for normalization. (C) Quantitative analysis of RPA data was performed using NIH image software.
vehicle-treated control colons using a general sPLA 2 substrate, HEPC, which is not reactive to cPLA 2 (25) . As shown in Figure 6A , no significant differences were found between the two groups. Furthermore, RPA analysis showed equivalent Fig. 7 . Examination of cPLA 2 and COX-2 in human colorectal tumors. mRNA levels of cPLA 2 and COX-2 in human colon tumor and matched normal colon specimens was determined by semi-quantitative RT-PCR analysis as described under Materials and methods. GAPDH was used as a loading control for normalization.
expression of group V and group X sPLA 2 mRNA in tumor and control tissue. Constitutive expression of the group X gene, however, was markedly higher relative to the group V, although the significance of these observations to the pathophysiology of the colon is not clear. Finally, we examined the expression of the M-type sPLA 2 receptor, which binds to group IB, IIA and group X sPLA 2 s and has been proposed to play an important role in regulating the activity of these enzymes (31, 32) . As shown in Figure 6B and C, results by RPA indicated no significant difference between the normal colon and tumor tissues. These results indicate that sPLA 2 levels are not correspondingly elevated in A/J colon tumors that have sustained a significant reduction in cPLA 2 expression. The data suggest that AA production may be compromised as a result of the down regulation of cPLA 2 . Reduced AA production, combined with increased AA utilization resulting from up regulation of COX-2, might actually lead to reduced levels of AA within the tumor cells. cPLA 2 and COX-2 expression in human colorectal tumors To examine the relationship between of cPLA 2 and COX-2 in human CRC, mRNA levels were determined by semiquantitative RT-PCR analysis. Reduced mRNA levels of cPLA 2 was found in all five of the tumor samples examined, whereas overexpression of COX-2 was found in four out of five of the samples (P Ͻ 0.01, Figure 7 ). Immunohistochemistry also demonstrated diminished cPLA 2 staining in human colon tumors compared with adjacent normal-appearing epithelium (Figure 8 ). The intense perinuclear staining of cPLA 2 observed in our study is in agreement with an earlier report by Schievella et al. (33) in which the subcellular localization of cPLA 2 was localized to the nuclear envelope and endoplasmic reticulum (33) . The data from human tissues are consistent with the expression patterns observed in carcinogen-exposed mouse colon, indicating that alterations in AA levels may also occur in human colon tumors. cPLA 2 , AA and TNF-α-induced cell death TNF-α treatment results in the activation of cPLA 2 (11) . In a number of instances, cPLA 2 activation by TNF-α has been shown to be critical for TNF-α-induced apoptosis, potentially through the ability of AA to activate sphingomyelinase and increase ceramide production (5), although this phenomenon has not yet been demonstrated in colon cells. In the present study, we found a 2.8-fold increase in TNF-α expression within the mouse colon tumors ( Figure 9A ). To test the potential significance of these findings in tumors with compromised cPLA 2 activity, cultured immortalized mouse colonocytes (YAMC) were pre-treated with the cPLA 2 specific inhibitor, AACOCF 3, prior to a 6 h incubation with TNF-α. As shown in Figure 9C and D, a clear dose-response was observed. Cells treated with increasing concentrations of AAC-OCF 3 demonstrated more resistance to TNF-α-induced cell death. We also examined the activity cPLA 2 1 h after TNF-α treatment and found that, in the presence of 10 mM AACOCF 3 , there was an µ87% decrease in cPLA 2 activity ( Figure 9B ).
Discussion
COX-2 is overexpressed in~85% of human colon adenocarcinomas (34) . Several lines of evidence have demonstrated that COX-2 and its product, PGE 2 , play an important role in the promotion of intestinal tumorigenesis. For example, inactivation of COX-2 by the introduction of a null mutation in the COX-2 gene or the use of COX-2 selective inhibitors markedly reduces intestinal tumor formation in Apc n716 mice (26) . Sulindac, a general COX inhibitor, has also been shown to prevent colon tumorigenesis and reduce polyp size in familial adenomatous polyposis patients (35) . The protumorigenic effect of COX-2 has been attributed to its ability to enhance cell proliferation and angiogenesis, while inhibiting cell differentiation and apoptosis. The role of COX-2 and PGE 2 in AOM-induced colon tumorigenesis has also been reported (36) (37) (38) (39) . In the present study, we show that COX-2 overexpression can actually occur at an early stage during colon tumorigenesis and its overexpression is accompanied by overproduction of PGE 2 in the tumors.
The source of AA for COX-2 metabolism can be potentially derived from a number of phospholipase A 2 enzymes. A critical pathway is via the intracellular phospholipase (cPLA 2 ) that provides AA for COX-2 synthesis of PGs. Immune cells isolated from cPLA 2 knockout mice fail to produce eicosanoids during either the immediate-or delayed-phase response to pro-inflammatory stimuli, indicating that cPLA 2 can be a major source of AA for PG production (12) . Apart from its role in the inflammatory response, two recent studies have demonstrated that cPLA 2 also plays an important role in tumorigenesis. Targeted deletion of cPLA 2 can protect against the formation of small intestinal tumors in both Apc Min and ApcD 716 mice. Interestingly, colon tumor formation was unexpectedly increased in both of these mouse strains. The potential role of cPLA 2 in colon tumorigenesis uncovered by these studies prompted us to explore the expression and activity of cPLA 2 in a colon-specific cancer model. We found that cPLA 2 expression and activity were markedly reduced in AOM-induced colon tumors. Moreover, this reduction occurred at a relatively early stage of AOM-induced tumorigenesis. Thus, three independent studies using different mouse tumor models, each illustrate the lack of correlation between cPLA 2 and COX-2 during colon tumorigenesis. The data further suggest that the role of cPLA 2 in colon tumorigenesis may be fundamentally different from its protective role in the small intestine. Indeed, the tumorigenic process within different regions of the intestine may be driven by distinct pathophysiological mechanisms.
The question of whether secreted phospholipases may compensate for the observed decrease in cPLA 2 activity was also examined in the present study. No enhanced protein activity or expression was observed between tumor and normal colon tissues, indicating that sPLA 2 s are not correspondingly up regulated as a compensatory response to the loss of cPLA 2 . Thus, the loss of cPLA 2 without a compensatory increase in sPLA 2 , combined with increased COX-2 production of PGs, suggests the possibility that there may be a reduction in the steady-state levels of AA within the tumor cells.
To establish whether a similar pattern of alteration in these key AA-metabolizing enzymes may also be present in the human colon, an analysis of cPLA 2 and COX-2 expression was undertaken in colon tumors and adjacent normal tissue. A similar pattern of alteration was found, suggesting that an imbalance between AA production and utilization may also occur during human colon tumorigenesis. Soydan et al. (40) have also reported a decrease in cPLA 2 in 11 out of 17 human colon tumors compared with matching normal controls. In contrast to these findings, however, Dinberg et al. (41) demonstrated a 3-fold increase in cPLA 2 expression using RT-PCR analysis. However, it is not clear from this study how many of the 44 samples examined actually showed the increase.
A substantial amount of evidence indicates that cPLA 2 -generated AA can serve a second messenger function, signaling apoptosis by stimulating formation of ceramide production and activation of caspase (5) . Alternatively, generation of AA by guest on November 24, 2016 http://carcin.oxfordjournals.org/ Downloaded from Fig. 9 . TNF-α-induced cell death was attenuated by blocking cPLA 2 activity in YAMC cells. (A) mRNA levels of TNF-α in normal colon and tumor tissues were determined by RPA. GAPDH was used as a loading control for normalization. Quantitative analysis of mRNA levels was performed using NIH image analysis. (B) YAMC cells were incubated with different concentrations of AACOCF 3 for 2 h followed by sensitization to TNF-α-induced apoptosis by co-incubating with 25 µg/ml CHX for 1 h. Cells were then treated with 25 ng/ml TNF-α. One hour after TNF-α treatment, cPLA 2 activity in each cell lysate was assessed and expressed as a percent decrease relative to untreated cells (AACOCF 3 314 from phospholipids may disrupt the integrity of various cellular membranes, resulting in cell death (5) . Lending support to this mechanism, it has been shown that cPLA 2 inhibitors, or overexpression of an AA-modifying enzyme, fatty acid-CoA ligase 4 (FACL4), render cells resistant to TNF-α-induced apoptosis (6, 7) . On the other hand, overexpression of cPLA 2 can enhance cell death (6, 7) . In the present study, we demonstrate that by specifically blocking cPLA 2 activity in cultured mouse colonocytes (YAMC), cells become resistant to TNF-α-induced apoptosis. This activity of cPLA 2 may be particularly important in tumors, which maintain high levels of TNF-α expression. Therefore, it is possible that decreased AA release as a result of diminished cPLA 2 protein levels in colon may contribute to attenuated apoptotic response in vivo, thereby facilitating tumorigenesis.
